(CercleFinance.com) – Valneva reports positive pivotal phase III results in adolescents regarding the immunogenicity of its single-injection live attenuated chikungunya virus (CHIKV) vaccine candidate, VLA1553.
These pivotal data showed that a single dose induced a robust immune response in adolescents aged 12 to 18 years, confirming the excellent immunogenicity previously observed in adults.
The VLA1553-321 trial, conducted at several sites in Brazil among 754 adolescents, thus achieved its main objective. These new results complement the first phase III safety data announced for this trial last August.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
